Research Links Certain Antibodies in Lupus Patients to Increased Risk of Blood Clots
A breakthrough study identifies specific antibodies in lupus patients that significantly increase their risk of blood clots, paving the way for better risk assessment and targeted treatments.
Recent research from Johns Hopkins University School of Medicine highlights a significant connection between specific antibodies in lupus patients and an elevated risk of thrombotic events, including blood clots, strokes, and heart attacks. The study focused on anti-transcription factor A, mitochondrial (anti-TFAM) antibodies, which target an essential mitochondrial protein called TFAM that plays a key role in maintaining mitochondrial health and genetics. Damage to this protein has long been associated with lupus development.
In a detailed analysis published in the Annals of the Rheumatic Diseases, researchers showed that lupus patients with anti-TFAM antibodies were approximately 2.8 to 3.3 times more likely to experience blood clots, independent of other risk factors and autoantibodies usually linked to thrombosis, such as anti-phospholipid antibodies. The team examined blood samples from 158 lupus patients and 98 healthy controls, finding that about one-third of lupus participants tested positive for these antibodies.
The findings suggest that anti-TFAM antibodies may serve as a biomarker for identifying lupus patients at higher risk of thrombotic complications. This discovery could lead to improved strategies for early intervention and personalized treatment plans aimed at preventing severe clotting events.
Lead researcher Dr. Eduardo Gómez-Bañuelos emphasized the unexpected significance of these antibodies, originally investigated in the context of lupus nephritis. The study's results underscore a potential new pathway linking mitochondrial damage to clot formation in lupus beyond traditional autoantibodies. Future research aims to determine whether anti-TFAM antibodies actively contribute to clot formation or merely signal increased risk, which could offer new targets for therapeutic intervention.
Overall, this research deepens understanding of lupus-related thrombosis and highlights the importance of mitochondrial health and immune response in autoimmune disease management.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
How Hearing Loss and Loneliness Speed Up Cognitive Decline in Older Adults
New research shows that hearing impairment combined with loneliness can significantly speed up cognitive decline in seniors, emphasizing the importance of early hearing care and emotional support.
Innovative Leukemia-On-A-Chip Device Revolutionizes CAR T Therapy Testing
Researchers at NYU have developed the first immunocompetent leukemia-on-a-chip device, transforming how CAR T-cell therapies are tested and personalized, reducing reliance on animal models.
Why Antibiotic Resistance Threatens Global Health Like Climate Change
Antimicrobial resistance (AMR) is a rising global health threat comparable to climate change, requiring international cooperation and innovative research to slow its progression and develop new solutions.
Disparities in Maternal Outcomes: Higher Risks for Marginalized Groups in Planned Repeat C-Sections
Research reveals that Black and Latinx women face higher risks of severe maternal health complications during planned repeat cesareans, highlighting ongoing racial disparities in obstetric care.